CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-25 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −24,338 | $24.21 | $589K | 3,737,000 |
| 2023-09-28 | Vakiener Victoria Director | Sale | −1,550 | $26.33 | $41K | 21,734 |
| 2023-09-18 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +57,755 | $4.75 | $274K | 3,819,093 |
| 2023-09-18 | Anzalone Christopher Richard Chief Executive Officer | Sale | −31,523 | $28.00 | $883K | 3,787,570 |
| 2023-09-18 | Anzalone Christopher Richard Chief Executive Officer | Sale | −26,232 | $28.27 | $742K | 3,761,338 |
| 2023-09-18 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy) | +57,555 | 409,225 | ||
| 2023-07-03 | Oliver Tracie Chief Commercial Officer | Sale | −8,925 | $35.31 | $315K | 61,575 |
| 2023-06-30 | Hamilton James C Chief Discovery/Trans Medicine | Sale | −3,000 | $35.53 | $107K | 188,484 |
| 2023-06-27 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −15,000 | $36.20 | $543K | 381,704 |
| 2023-05-05 | GIVEN DOUGLAS B Director | Sale | −6,500 | $40.90 | $266K | 117,635 |
| 2023-05-04 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +50,000 | $2.01 | $101K | 3,811,338 |
| 2023-05-04 | Anzalone Christopher Richard Chief Executive Officer | Sale | −24,008 | $38.97 | $936K | 3,787,330 |
| 2023-05-04 | Anzalone Christopher Richard Chief Executive Officer | Sale | −25,992 | $40.02 | $1.0M | 3,761,338 |
| 2023-05-04 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy) | −50,000 | 466,980 | ||
| 2023-05-03 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +54,928 | $2.01 | $110K | 3,816,266 |
| 2023-05-03 | Anzalone Christopher Richard Chief Executive Officer | Sale | −54,928 | $39.14 | $2.1M | 3,761,338 |
| 2023-05-03 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy) | −54,928 | 516,980 | ||
| 2023-03-03 | OLUKOTUN ADEOYE Y Director | Sale | −11,350 | $32.65 | $371K | 7,867 |
| 2023-02-27 | GIVEN DOUGLAS B Director | Sale | −875 | $32.62 | $29K | 13,000 |
| 2023-01-10 | Ferrari Mauro Director | Grant or award | +7,867 | 50,838 |
Page 11 of 38 · 752 trades